- Home
- RLGT vs TNGX Comparison
RLGT vs TNGX Comparison
Compare RLGT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLGT
- TNGX
- Stock Information
- Founded
- RLGT 2001
- TNGX 2014
- Country
- RLGT United States
- TNGX United States
- Employees
- RLGT N/A
- TNGX N/A
- Industry
- RLGT Oil Refining/Marketing
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RLGT Consumer Discretionary
- TNGX Health Care
- Exchange
- RLGT Nasdaq
- TNGX Nasdaq
- Market Cap
- RLGT 280.5M
- TNGX 723.2M
- IPO Year
- RLGT N/A
- TNGX N/A
- Fundamental
- Price
- RLGT $5.96
- TNGX $7.62
- Analyst Decision
- RLGT Strong Buy
- TNGX Strong Buy
- Analyst Count
- RLGT 1
- TNGX 6
- Target Price
- RLGT $8.00
- TNGX $10.00
- AVG Volume (30 Days)
- RLGT 163.2K
- TNGX 1.5M
- Earning Date
- RLGT 09-15-2025
- TNGX 11-05-2025
- Dividend Yield
- RLGT N/A
- TNGX N/A
- EPS Growth
- RLGT 118.75
- TNGX N/A
- EPS
- RLGT 0.35
- TNGX N/A
- Revenue
- RLGT $902,696,000.00
- TNGX $24,296,000.00
- Revenue This Year
- RLGT $7.61
- TNGX $20.42
- Revenue Next Year
- RLGT N/A
- TNGX N/A
- P/E Ratio
- RLGT $17.06
- TNGX N/A
- Revenue Growth
- RLGT 12.49
- TNGX N/A
- 52 Week Low
- RLGT $5.44
- TNGX $1.03
- 52 Week High
- RLGT $7.94
- TNGX $9.84
- Technical
- Relative Strength Index (RSI)
- RLGT 41.38
- TNGX 63.92
- Support Level
- RLGT $6.37
- TNGX $6.38
- Resistance Level
- RLGT $6.95
- TNGX $6.90
- Average True Range (ATR)
- RLGT 0.19
- TNGX 0.45
- MACD
- RLGT -0.04
- TNGX 0.05
- Stochastic Oscillator
- RLGT 0.00
- TNGX 80.12
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.